<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742920</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0362</org_study_id>
    <nct_id>NCT04742920</nct_id>
  </id_info>
  <brief_title>The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS)</brief_title>
  <acronym>OTEMACS</acronym>
  <official_title>The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Middle meningeal artery (MMA) embolization via a minimally invasive endovascular approach&#xD;
      might increase the likelihood of resolution and might prevent reaccumulation of Chronic&#xD;
      Subdural Hematoma (CSDH). The purpose of the OTEMACS Trial is to assess the safety and effect&#xD;
      on recurrence rate and functional outcome of endovascular treatment in patients with CSDH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OTEMACS study is a prospective, multicenter clinical trial with randomized treatment&#xD;
      allocation, open label treatment and blinded endpoint evaluation (PROBE), designed to&#xD;
      demonstrate that MMA embolization via a minimally invasive endovascular approach combined&#xD;
      with standard (surgical/conservative) management is superior to standard management alone, in&#xD;
      reducing the rate of CSDH-related surgical interventions and the recurrence rate in patient&#xD;
      with CSDH at 90 days.&#xD;
&#xD;
      Eligible symptomatic CSDH patients will be randomly assigned, in a 1:1 ratio, to receive&#xD;
      either surgical treatment plus an adjuvant MMA embolization (ST+MMAE group; the Experimental&#xD;
      arm) or surgical treatment alone (ST group; the Control arm).&#xD;
&#xD;
      Eligible symptomatic nonsurgically treated patients with CSDH will be randomized, in a 1:1&#xD;
      ratio, to MMA embolization (MMAE group; the Experimental arm) or conservative management (CM&#xD;
      group; the Control arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate in the Experimental group vs. the Control group</measure>
    <time_frame>Within 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates at discharge</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major disabling stroke at discharge</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of procedure-related and device-related serious adverse events (PRSAEs and DRSAEs)</measure>
    <time_frame>Through 24 hours (-6/+24 hours) post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence of CSDH requiring revision surgery (in surgical group) or surgical rescue (in non-surgical group)</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hematoma volume (HV) in the Experimental group vs. the Control group</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift on the modified Rankin Scale (mRS) score in the Experimental group vs. the Control group</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with good functional outcome, defined as mRS 0-2</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with favorable functional outcome, defined as mRS 0-3</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of disability (shift on the mRS combining scores of 5 and 6)</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of utility weighted mRS (UW mRS)</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by the EuroQol (Quality of life) EQ-5D scale</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by the Barthel Index</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay for neurosurgery.</measure>
    <time_frame>within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>At 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Hematoma, Subdural, Chronic</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Wounds and Injuries</condition>
  <arm_group>
    <arm_group_label>MMA embolization group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MMA embolization procedure with Onyx™ in addition to standard (surgical/conservative) management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard (surgical/conservative) Management alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Middle Meningeal Artery Embolization</intervention_name>
    <description>MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 24 hours after randomization in addition to standard management</description>
    <arm_group_label>MMA embolization group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Management</intervention_name>
    <description>Procedure : Surgical Management Surgical evacuation of the subdural hematoma&#xD;
Other: Conservative Management Standard medical management: drug treatment and/or observation</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥ 18 years old at inclusion (no upper age limit).&#xD;
&#xD;
          -  CSDH confirmed on cranial imaging (e.g. CT/magnetic resonance imaging [MRI]), as&#xD;
             documented by a radiologist.&#xD;
&#xD;
          -  One or more symptoms attributable to CSDH including headache, cognitive impairment,&#xD;
             gait instability, seizure, mild focal neurologic deficit, speech disturbance, or&#xD;
             decreased consciousness.&#xD;
&#xD;
          -  No significant pretreatment disability (baseline mRS score ≤3).&#xD;
&#xD;
          -  Patient or patient's representative has received information about the study and has&#xD;
             signed and dated the appropriate Informed Consent Form, or fulfilling the criteria for&#xD;
             emergency consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CSDH developing with underlying conditions: vascular lesions, brain tumor, arachnoid&#xD;
             cyst, or spontaneous intracranial hypotension.&#xD;
&#xD;
          -  CSDH that have a focal location (confined to the frontal or temporal base or the&#xD;
             interhemispheric space without cerebral convexity involvement), is 10 mm or less in&#xD;
             thickness, or have no mass effect (cortical flattening or midline shifting).&#xD;
&#xD;
          -  Known absence of vascular access or any local cause prohibiting femoral&#xD;
             catheterization.&#xD;
&#xD;
          -  Known contrast or endovascular or anesthetic product allergy or contraindications.&#xD;
&#xD;
          -  Any contraindications to the use of the Onyx™.&#xD;
&#xD;
          -  Female who is known to be pregnant or lactating at time of admission.&#xD;
&#xD;
          -  Patient presenting severe or fatal co-morbidities or Life expectancy under 6 months&#xD;
             that will likely interfere with improvement or follow-up or that will render the&#xD;
             procedure unlikely to benefit the patient.&#xD;
&#xD;
          -  Patient unable to be present or available for follow-up&#xD;
&#xD;
          -  Pre-existing neurological or psychiatric disease that would confound the neurological&#xD;
             or functional evaluations (e.g. severe dementia).&#xD;
&#xD;
          -  Current participation in another investigational drug or device study.&#xD;
&#xD;
          -  Major patients under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>115 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent COSTALAT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imad DERRAZ, MD</last_name>
    <phone>+33 (0)4 67 33 75 32</phone>
    <email>i-derraz@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu de Montpellier - Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent COSTALAT</last_name>
      <email>v-costalat@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Imad DERRAZ</last_name>
      <email>i-derraz@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Subdural Hematoma</keyword>
  <keyword>Middle Meningeal Artery</keyword>
  <keyword>Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

